Loading organizations...
§ Private Profile · 215 First Street, Suite 401 Cambridge, MA 02142
Thymmune Therapeutics is a technology company.
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform designed to restore normal immune function. The company's core product leverages induced pluripotent stem cell (iPSC) manufacturing to generate off-the-shelf thymic cells at scale, aiming to provide a reproducible and less invasive therapeutic approach. This technology addresses the challenge of immune decline by producing functional thymic cells that are crucial for T cell development.
Stan Wang, MD, PhD, founded Thymmune Therapeutics, building upon the critical insight that the natural degradation of the thymus with age leads to significant immune dysfunction. Recognizing the limitations of existing methods, the company originated to develop a scalable and advanced solution through its proprietary engineering platform, focusing on mass production of iPSC-derived thymic cells to overcome previous therapeutic bottlenecks.
The company's pipeline targets a range of conditions including immunodeficiencies, transplant-related complications, and autoimmune disorders. Thymmune's vision is to transform immunology by offering novel therapies that not only treat specific immune system pathologies but also address the fundamental biology of immune decline, ultimately contributing to healthier aging for a broad patient population.
Thymmune Therapeutics has raised $44.0M across 2 funding rounds.
Thymmune Therapeutics has raised $44.0M in total across 2 funding rounds.
Thymmune Therapeutics has raised $44.0M across 2 funding rounds. Most recently, it raised $37.0M Other Equity in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 14, 2024 | $37M Venture Round | Advanced Research Projects Agency For Health | — | Announced |
| Feb 1, 2023 | $7M Seed | Thomas DE Vlaam | Catalio Capital, Flagship Ventures, Third Rock Ventures, George Church, James Fordyce, John Maraganore, Judy Pagliuca, Mark Bamforth OBE, Philip Reilly, Christopher D. Hillyer | Announced |
Thymmune Therapeutics has raised $44.0M in total across 2 funding rounds.
Thymmune Therapeutics's investors include Advanced Research Projects Agency for Health, Thomas de Vlaam, Catalio Capital, Flagship Ventures, Third Rock Ventures, George Church, James Fordyce, John Maraganore, Judy Pagliuca, Mark Bamforth OBE, Philip Reilly, Christopher D. Hillyer.
Thymmune Therapeutics is a preclinical biotechnology company developing a machine learning-driven platform for thymic cell engineering to restore immune function in patients with immunodeficiencies, transplant-related issues, autoimmune disorders, and age-related immune decline.[1][2] It produces scalable, off-the-shelf iPSC-derived thymic cells, targeting conditions like athymia through therapies such as THY-001, which differentiates thymic epithelial progenitor cells (TEPs) into functional thymic tissues.[2][5] Based in Cambridge, Massachusetts, the company has raised over $600 million in funding, including a $380 million Series C in 2023 that valued it at $1 billion, demonstrating strong growth momentum fueled by seed ($7 million), Series A ($13 million), and government support like a $1 million SBIR Phase II award.[1][2][5]
Founded in 2019 in Cambridge, Massachusetts, Thymmune emerged from decades of research on the thymus gland, a critical immune organ that declines with age and disease, leading to vulnerabilities like immunodeficiencies.[1][2] The idea leverages proprietary insights in thymic engineering, using iPSC-derived cells to regenerate thymic function in a scalable way, addressing gaps in current treatments.[4][5] Early traction included $7 million in seed funding led by Pillar VC and NYBC Ventures in 2021, followed by $13 million to advance preclinical studies, and recent bolstering of its leadership with biopharmaceutical veterans, including head of corporate development Supratim Das.[1][2] Pivotal moments include ARPA-H funding as the first industry project under its Open Broad Agency Announcement and an SBIR Fast Track grant to optimize THY-001 production for clinical trials.[2][5]
Thymmune rides the wave of regenerative immunology and iPSC cell therapy, a booming sector addressing the global rise in immune disorders from aging populations, transplants, and autoimmunity—market forces amplified by advances in AI-driven biomanufacturing and stem cell scalability.[1][2] Timing is ideal amid surging biotech investments in "off-the-shelf" cell therapies, which reduce costs and patient wait times compared to autologous methods, positioning Thymmune to influence healthier aging and post-transplant care ecosystems.[2][5] As part of NYBC Ventures' focus on blood and cell therapies, it fosters partnerships with research labs and accelerates innovation in transfusion medicine and infectious disease responses.[3]
Thymmune is primed to advance THY-001 into IND-enabling studies and clinical trials, leveraging its SBIR progress and $600 million war chest to scale manufacturing and test in large preclinical models.[1][5] Trends like AI-optimized cell engineering and ARPA-H-backed projects will shape its path, potentially expanding to Phase 1 trials by 2026-2027 for athymia and beyond. Its influence could evolve into a leader in thymic rejuvenation, transforming immune restoration from niche to standard care and enabling broader applications in aging biotech. This positions Thymmune as a high-momentum player restoring immune resilience at scale.